National Cancer Center

What National Cancer Center does

National Cancer Center (NCC, 국립암센터) is South Korea's government-designated national cancer center, operating under the Ministry of Health and Welfare as a state-owned research hospital headquartered in Goyang, Gyeonggi Province. The institution integrates four divisions under one governance structure: a Research Institute conducting public-interest cancer research, an affiliated hospital with 13 organ-specific cancer centers (covering rare, sarcoma, pediatric/adolescent, lung, hepatobiliary-pancreatic, colorectal, gastric, breast, gynecologic, thyroid, urologic, and hematologic cancers), a National Cancer Control Headquarters overseeing cancer registration, prevention, screening, big data, hospice, and survivorship programs, and the International Cancer Graduate School University. Core clinical capabilities include advanced modalities such as proton therapy, hematopoietic stem cell transplantation, and a liver transplant program that has performed over 900 living-donor liver transplants since 2005 with an 84.1% five-year survival rate for primary hepatocellular carcinoma patients.

The center's research infrastructure comprises CoreLab facilities offering genomics, proteomics, bioinformatics, animal molecular imaging, flow cytometry, microscopy, biostatistics, and biobank services, supported by an AAALAC-accredited animal facility with capacity for up to 30,000 rodents. NCC is developing the Biological World Model, a generative AI trained on cell experiment results to predict drug efficacy in organoids and animal models, funded as part of a 22.5 billion won ($15M) four-year Ministry of Science and ICT project. The National Cancer Big Data Center and Central Cancer Registry provide national-scale cancer surveillance infrastructure, and the institution maintains international research collaborations with UICC, IARC, NCI, and Japan's National Cancer Center.

As a government state entity rather than a commercial enterprise, NCC is funded primarily through national health insurance reimbursements and direct government budget allocations. It holds no private investors or shareholders. Services are delivered through the hospital, the CoreLab fee-for-use infrastructure (e.g., 30,000 KRW/hour for small animal MRI to university and research institute users), and national cancer management programs distributed via regional cancer center networks and a referral coordination office. The institution operates within Korea's national public healthcare infrastructure, with no disclosed revenue and no commercial ownership structure.

Name

National Cancer Center

Legal name

National Cancer Center

Website

https://ncc.re.kr

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

National Cancer Center (국립암센터) is South Korea's government-designated national cancer center under the Ministry of Health and Welfare, operating an integrated hospital, research institute, national cancer control programs, and graduate school. It serves Korean cancer patients, domestic researchers, and national policy needs with 13 specialized cancer centers, advanced core research facilities, and a developing AI-driven drug prediction platform.

Ownership category

akta.pro rank

Product category

Cancer Hospital and Research Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (622310), Diagnostic Imaging Centers (621512), General Medical and Surgical Hospitals (622110)

SIC

Services-Hospitals (8060), Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Medical Oncology (HLAKAFAB), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Oncology Specialty Pharmaceuticals (HLAIACAA), Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI)

Keywords

• Cancer treatment services
• Oncology research
• Cancer screening programs
• Clinical trials
• Hospice palliative care

Headquarters

HQ city

Koyang

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Pricing tiers

Distribution channels3 records

Marketing channels3 records

Core offering

National Cancer Center provides integrated cancer care, research, and national cancer management services through its affiliated hospital (13 specialized cancer treatment centers, proton therapy, transplantation, hospice), research institute (genomics, proteomics, bioinformatics, drug discovery, AI), and national cancer control headquarters (registry, screening, prevention, policy). It serves cancer patients directly, supports universities and research institutes with shared CoreLab infrastructure, and operates national cancer surveillance and policy programs on behalf of the South Korean government.

Product overview

National Cancer Center Korea operates as a comprehensive national cancer center providing integrated cancer care services across prevention, diagnosis, treatment, and research. The center offers a multi-center treatment model with specialized cancer-specific centers (Rare Cancer, Sarcoma, Pediatric/Adolescent, Lung, Hepatobiliary-Pancreatic, Colorectal, Gastric, Breast, Gynecologic, Thyroid, Urologic, and Hematologic Cancer Centers), advanced research core facilities (genomics, proteomics, bioinformatics, molecular imaging, flow cytometry, microscopy, and biobank), proton therapy, hospice/palliative care, and organ/stem cell transplantation services. Research infrastructure includes cancer data science and AI research, treatment guidelines development, and a national cancer big data center. The organization operates through affiliated hospital, research institute, national cancer management headquarters, and international cancer graduate school university divisions.

Differentiator

Problem solved

Functional benefit

Products and services

• Cancer Treatment Centers (13 Specialized Centers) Comprehensive cancer treatment through organ-specific specialized centers covering rare cancer, sarcoma, pediatric/adolescent, lung, hepatobiliary-pancreatic, colorectal, gastric, breast, gynecologic, thyroid, urologic, and hematologic cancers.
• Cancer Research Core Facilities (CoreLab) Shared research infrastructure services for internal and external researchers covering genomics, proteomics, bioinformatics, animal molecular imaging, flow cytometry, microscopy imaging, biobanking, and biostatistics support.
• Hospice and Palliative Care Services Multidisciplinary hospice and palliative care for terminal cancer patients including inpatient, home-based, and consultation-based care, with pain management, psychological/social/spiritual care, and bereavement support.
• Hematopoietic Stem Cell Transplantation Services Comprehensive stem cell transplantation program including allogeneic, autologous, unrelated donor, cord blood, and ABO-incompatible transplants, with 8 rooms and 14 sterile beds.
• Liver Transplantation Services Living donor liver transplantation program including ABO-incompatible transplants, with 900+ transplants performed as of April 2025 and an 84.1% 5-year survival rate for primary liver cancer patients.
• Cancer Data Science and AI Research Cancer data science research covering bioinformatics, cancer epidemiology, and integrative biostatistics with advanced computational infrastructure and AI/big data analytics.
• Cancer Treatment Guidelines Development Development and dissemination of evidence-based standardized cancer treatment guidelines across cancer types in collaboration with medical societies, aiming to improve treatment outcomes and reduce regional disparities.
• Proton Therapy Center Advanced proton beam radiotherapy services for cancer treatment with specialized equipment and clinical expertise.
• National Cancer Big Data Center National cancer registry, surveillance, and big data infrastructure for cancer management policy research, population-based monitoring, and cancer data utilization.
• DEL CoreBank Drug Discovery Platform DNA-Encoded Library technology platform for drug discovery capable of screening tens of millions of compounds simultaneously to identify candidate cancer therapeutics.

Quantifiable outcome

• Excellent outcomes in public benefit cancer research with multiple SCIE publications including high-impact journals (e.g., Cancer Cell, Nature Communications, Gastroenterology)
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• National Cancer Center Japan: Japan's government-designated national cancer center in Tokyo, operating an integrated cancer hospital, research institute, and cancer control division — the closest structural analog to NCC Korea with the same national mandate model.
• National Cancer Institute (US NCI): US federal agency for cancer research and training, part of NIH. Comparable mandate for national cancer research, surveillance, and policy, though NCC Korea combines a hospital while NCI primarily funds extramural research.
• German Cancer Research Center (DKFZ): Germany's national biomedical research institute focused on cancer, operated under the Helmholtz Association. Comparable large-scale government-funded cancer research infrastructure and translational programs.
• Gustave Roussy Institute: Leading European comprehensive cancer center and hospital near Paris, combining research, treatment, and teaching. Comparable integrated specialty hospital + research institute model with national referral role.
• IARC (International Agency for Research on Cancer): WHO's specialized cancer research agency coordinating global cancer surveillance and epidemiology. Directly comparable on national/international cancer registration, data management, and policy research mandate.

Broad incumbents

• MD Anderson Cancer Center: US-based comprehensive cancer hospital and research center affiliated with University of Texas. Comparable in multi-disease oncology specialty depth, proton therapy, and translational research, but operates as a hybrid public-private institution with global patient catchment.
• Samsung Medical Center (Cancer Center): Major Korean private tertiary hospital operating one of Seoul's largest comprehensive cancer centers. Directly comparable on multi-disciplinary oncology care in Korea but with private/commercial agility that NCC lacks.
• Asan Medical Center: Seoul-based private academic medical center with a large cancer hospital and research institute. Comparable in clinical volume, transplant programs, and oncology research output in the Korean market.
• Seoul National University Hospital (Cancer Hospital): Korea's flagship public academic medical center with a dedicated cancer hospital. Comparable in research-clinical integration, government affiliation, and academic standing as a national referral center.
• Memorial Sloan Kettering Cancer Center: US-based specialty cancer hospital and research institute. Comparable in multi-disciplinary specialty oncology depth and translational research, but operates as a private non-profit with global patient and trial footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/nationalcancercenterkorea
• LinkedInlinkedin.com/company/ncc-korea

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about National Cancer Center